Genmab — September 2022
-
Asien: Investorerne genoptager negativ spiral https://www.proinvestor.com/investornyt/884038/asien-investorerne-genoptager-negativ-spiral
-
Onsdagens danske aviser med Mærsk, Danske Bank og Nets https://www.proinvestor.com/investornyt/884037/onsdagens-danske-aviser-med-maersk-danske-bank-og-nets
-
Aktier/tendens: Kursfald på vej inden Carlsberg holder hof
-
Ekstreme USD stigning fortsætter og viser investorfrygt - USD bonanza venter i 2023 for dansk life science https://www.proinvestor.com/boards/106424
-
Danmark/AL: Sjette måned i år med svindende aktieformuer hos danskerne https://www.proinvestor.com/investornyt/884066/danmark-al-sjette-maned-i-ar-med-svindende-aktieformuer-hos-danskerne
-
Aktier/åbning: Ny mavepuster sender C25 nær toårig bund
https://proinvestor.com/investornyt/884072/aktier-abning-ny-mavepuster-sender-c25-naer-toarig-bund -
IBCL-460 Subcutaneous Epcoritamab With Rituximab + Lenalidomide (R2) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Update from Phase 1/2 Trial https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(22)01565-8/pdf
-
ABCL-439 Subcutaneous Epcoritamab With Gemcitabine + Oxaliplatin (GemOx) Induced High Response Rates in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Ineligible for Autologous Stem Cell Transplant (ASCT) https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(22)01541-5/fulltext
-
ABCL-422 Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(22)01540-3/fulltext
-
@Fritten - der har været en del kommentarer de seneste måneder angående USD/DKK endvidere blev opjusteringen ved Q2 delvist forklaret med høj FX.
-
og det er småpenge i forhold til "finansiel" valutagevinst på kontantbeholdningen, hvor Genmab bogførte 1,8 mia. kr. i 1. halvår.
-
Genmab burde kurssikre de næste 3 års $ indtægter mod €.
-
Biogen +50% pre market on Alzheimer’s drug results; should lift bio- indices a bit (pretty big in % IBB / XBI ) https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-says-alzheimers-drug-succeeds-slowing-cognitive-decline-2022-09-27/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind